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Abstract
Background: The signal transduction pathways mediated by retinoic acid play a critical role in the
regulation of cell growth and differentiation during embryogenesis and hematopoiesis as well as in
a variety of tumor cell lines in culture. Following the reports that two members of the superfamily
of aldehyde dehydrogenase (ALDH) enzymes, ALDH1A1 and ALDH1A2, were capable of
catalyzing the oxidation of all-trans retinal to all-trans retinoic acid with submicromolar Km values,
we initiated an investigation of the ability of 4-(N,N-dipropylamino)benzaldehyde (DPAB) to inhibit
the oxidation of retinal by purified mouse and human ALDH1A1.
Results: Our results show that DPAB potently inhibits retinal oxidation, with IC50 values of 0.11
and 0.13 µM for purified mouse and human ALDH1A1, respectively. Since the HL-60 human
myeloid leukemic cell line has been used extensively to study the retinoic acid induced
differentiation of HL-60 cells to granulocytes, and ALDH1A1 activity had previously been reported
in HL-60 cells, we investigated the ability of DPAB to block differentiation of HL-60 promyelocytic
leukemia cells exposed to retinal in culture. In HL-60 cells coincubated with 1 µM retinal and 50
µM DPAB for 144 hours, cell differentiation was inhibited only 30%. Furthermore, the NAD-
dependent oxidation of propanal or retinal was less than 0.05 nmoles NADH formed/min-107 cells
in spectrophotometric assays using HL-60 cell extracts.
Conclusions: Although ALDH1A1 may be the major catalytic activity for retinal oxidation in some
retinoid-dependent mouse and Xenopus embryonic tissues and in adult human and mouse
hematopoietic stem cells, another catalytic activity appears to synthesize the retinoic acid ligand
necessary to stimulate the differentiation of HL-60 cells to end stage granulocytes.
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Background
The aldehyde dehydrogenase (ALDH) superfamily of en-
zymes consists of a group of NAD(P)-dependent enzymes
which can oxidize a structurally diverse group of endog-
enous and exogenous aldehyde substrates. Seventeen
ALDH genes have been identified in the human genome
and have been classified into ten different families based
on amino acid sequence identities [1,2]. High levels of
ALDH1A1 activity can protect human and murine cells
from the toxicity of the alkylating agent cyclophospha-
mide and its oxazaphosphorine analogs. Indeed it was hy-
pothesized that the high expression of ALDH1A1
(formerly known as class 1 ALDH) was responsible for the
successful use of cyclophosphamide in tumor cell purging
regimens during bone marrow transplantation [3]. The
detection of elevated ALDH1A1 activity in the most prim-
itive human hematopoietic progenitor cells [4–6] has pro-
vided evidence in support of this hypothesis. However, no
physiologic role for this enzyme in the hematopoietic
stem cell population has been identified.
Vitamin A (retinol) is the prototype of a class of natural
and synthetic chemical compounds named the retinoids.
Retinoids are found in a variety of chemical oxidation
states, including alcohol, aldehyde, ester, and carboxylic
acid functionalities. The acid form, retinoic acid, is a plei-
otropic hormone which regulates gene expression in em-
bryonic development, epithelial cell differentiation,
hematopoeisis, and tumor cell formation.
Several enzymes, including isoforms of alcohol dehydro-
genase, ALDH, and cytochrome P450 (CYP), recently
have been shown to be involved in the formation of retin-
oic acid from retinol and retinal [7,8]. The purification,
cloning, and characterization of several ALDH enzymes
which efficiently catalyze the oxidation of retinal (Figure
1A) has suggested that regulation of retinoic acid forma-
tion could be a key physiologic role for these enzymes.
The report of the crystal structure of the homotetrameric
ALDH1A1 enzyme from sheep liver revealed a substrate
tunnel capable of binding retinal which was absent in
ALDH2 and ALDH3A1 enzymes [9]. Likewise, the crystal
structure reported for mouse ALDH1A2 revealed a sub-
strate channel which could provide specificity for retinal
and exclude short-chain aliphatic aldehydes [10].
The specific role of each enzyme in the regulation of retin-
oid signalling may depend on the species, cell type, and
developmental status of the cell. In vitro, purified mouse
[11], human [12], and Xenopus[13] ALDH1A1 can effi-
ciently oxidize all-trans retinal to all-trans retinoic acid. In
vivo, the introduction of ALDH1A1 mRNA into Xenopus
embryos induces early synthesis of retinoic acid, while
ALDH1A1 expression is detected during the tail bud stages
of Xenopus embryogenesis [14]. ALDH1A2 in the mouse
[15] and rat [16] has shown even greater specificity and
catalytic efficiency for retinal as a substrate. Immuno-his-
tochemical analysis of mouse embryos shows that
ALDH1A1 expression occurs primarily in cranial tissues,
while ALDH1A2 expression occurs primarily in trunk tis-
sue [17]. In addition, the targeted knockout of the
ALDH1A2 gene in mice results in a significant decrease in
retinoic acid biosynthesis and early embryo death [18].
The development of inhibitors which can target individu-
al ALDH enzymes provides one approach for addressing
the role of a specific ALDH enzyme in the oxidation of ret-
inal to retinoic acid in a given cell type. We have identified
4-(N, N-dipropylamino)benzaldehyde (DPAB) (Figure
1B) and 4-(N, N-diethylamino) benzaldehyde (DEAB) as
potent, selective inhibitors of ALDH1A1, but not ALDH2
or ALDH3, with the dipropyl analog exhibiting 10-fold
greater efficacy for inhibition [19,20]. The effect of DPAB
on ALDH1A2 has not been reported.
Figure 1
Chemical structures for ALDH1A1 substrate and inhibitor.
(A) substrate: all-trans retinal. (B) inhibitor: 4-(N,N-dipro-
pylamino)benzaldehyde (DPAB).
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DEAB was first used to sensitize the mouse leukemic cell
line L1210/CPA, which is resistant to 4-hydroperoxycy-
clophosphamide (4-HC) by virtue of its overexpression of
ALDH1A1. Treatment of L1210/CPA cells in vitro with 50
µM DEAB abolished the tumor cells' resistance to 4-HC
[19]. DEAB also exhibited in vivo efficacy as a ALDH1A1
inhibitor, as demonstrated by the toxicity to the intestinal
crypt cells in mice receiving co-injections of DEAB and cy-
clophosphamide [21]. More recently, DEAB has been
used to demonstrate that overexpression of human
ALDH1A1 in transfected cell lines is sufficient to cause cel-
lular resistance to the oxazaphosphorines [22] and 4-HC
[23]. DEAB has also been an effective reagent in fluores-
cent-activated cell sorting (FACS) techniques to isolate
human hematopoietic stem cells based on the expression
o f  A L D H 1 A 1  a c t i v i t y  [ 5 , 6 ] .  I n  c o n t r a s t  t o  D E A B  a n d
DPAB, daidzin – a natural product isolated from Pueraria
lobata (the Kudzu plant) – shows specificity for inhibiting
ALDH2 at concentrations similar to that of DPAB used to
inhibit ALDH1A1 [24,25]. An inhibitor specific for
ALDH1A2 has not yet been reported.
In normal hematopoiesis, terminally differentiated cells
are generated daily from a limited number of pluripotent
stem cells. The stem cell population must be exquisitely
regulated to ensure sufficient self-renewal as well as com-
mitment to progenitor cells which can give rise to mature
erythrocytes, platelets, lymphocytes, granulocytes, and
macrophages. Retinoic acid appears to elicit a complex re-
sponse of cell proliferation and/or commitment to a more
differentiated cell type, depending on the differentiation
state of the cell receiving the signal [26,27].
The HL-60 human promyelocytic leukemia cell line re-
sponds in culture to sub-micromolar concentrations of
retinoic acid (all-trans and 13-cis) by undergoing terminal
differentiation to a granulocytic cell with the ability to
phagocytose and reduce nitroblue tetrazolium [28]. The
response to retinoic acid in HL-60 cells is dependent on
the expression of the retinoic acid receptor RAR α  [29].
The use of all-trans retinoic acid in differentiation therapy
for patients with acute promyelocytic leukemia has result-
ed in prolonged, complete remissions when combined
with cytotoxic chemotherapy, and may provide complete,
long-term remissions as a single agent [30].
However, the enzyme or enzymes responsible for the for-
mation of retinoic acid in the HL60 cells have not been
identified. In one report, ALDH1A1 protein was not de-
tected by Western blot, but enzyme activity was detected
using flow cytometry and a fluorescent aldehyde substrate
[5]. In a second study, ALDH1A1 protein was detected us-
ing an ELISA assay and activity was detected using aldo-
phosphamide as substrate [31]. In these two studies,
designed to look at the relationship of ALDH1A1 activity
to antitumor drug resistance, the levels of ALDH1A1 were
low in HL-60 compared to other cell types, corresponding
to the sensitivity of HL-60 cells to oxazaphosphorines.
ALDH activity has been reported in HL-60 cells using 4-
hydroxynonenal as substrate [32]. However, since this
molecule is such a poor substrate with ALDH1 compared
to ALDH3, the measured activity likely represents only
ALDH3 activity. ALDH3 does not oxidize all trans retinal.
Expression of ALDH1A2 activity in HL-60 cells has not
been reported. Therefore, we chose the HL-60 cell line to
assess the role of ALDH1A1 in the oxidation of retinal.
The collection of results demonstrating that retinal is an
excellent substrate for ALDH1A1 in vitro, that ALDH1A1 is
responsible for the synthesis of retinoic acid in the cranial
tissues of the mouse embryo, and that hematopoietic
stem cells are characterized by high expression of
ALDH1A1, have led to the hypothesis that the oxidation
of retinal to retinoic acid is a key physiologic role for
ALDH1A1 in hematopoietic stem cells. Our long-term
goal is to use DPAB to investigate the role of ALDH1A1 in
retinoic acid biosynthesis at different stages of hemat-
opoiesis. In this paper we show that DPAB is a potent in-
hibitor of retinal oxidation by murine and human
ALDH1A1. However, DPAB only weakly inhibits the reti-
nal-induced differentiation of HL-60 cells, suggesting that
ALDH1A1 is not the operative retinal oxidizing enzyme in
these cells.
Results and discussions
DPAB is a potent inhibitor of retinal oxidation with IC50
values of 0.11 and 0.13 µM for purified mouse and hu-
man ALDH1A1, respectively (Table 1). These IC50 values
are 100-fold lower than the retinal concentrations used in
the assay. The IC50 values for mouse ALDH1A1 are be-
tween the values observed with propanal (0.040 µM) and
phenylacetaldehyde (0.36 µM) as substrates, with the hu-
man ALDH1A1 showing the same inhibition with retinal
or propanal as substrate. The IC50 values reported were in-
itially obtained from spectrophotometric assays, and re-
peated with an HPLC assay. We were concerned with
using a spectrophotometric assay for these inhibition
studies due to the presence of several absorbing species at
340 nm, including NADH, DPAB, retinal, and retinoic ac-
id. Thus, we modified an HPLC assay in order to directly
measure the amount of retinoic acid product formed. Pre-
vious reports of HPLC assays for ALDH reactions with tis-
sue extracts used a single time point at 60 min to measure
accumulation of product, after documenting that retinoic
acid formation was still linear in time course experiments
[33]. In our hands, the reaction with purified enzyme was
only linear for product formation up to 10–15 minutes.
Following continuous exposure to 1 µM retinoic acid for
96 hours, almost 40% of cells have differentiated to gran-BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/4
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ulocytes, as seen by the positive NBT staining. Exposure to
1 µM all-trans retinal for 96 hours induced differentiation
equivalent to exposure to 0.05–0.1 µM retinoic acid. With
co-exposures to 1 µM retinal and up to 50 µM DEAB or
DPAB, HL-60 differentiation was inhibited by only 30%
after 144 hours of exposure, compared with cells exposed
to retinal alone (Figure 2) DPAB did not alter the induc-
tion of differentiation by retinoic acid, nor did it affect cell
viability up to 144 hours. Since DPAB's inhibition of cell
differentiation in cells exposed to retinal was so low, we
needed to demonstrate that chemical oxidation or any se-
rum enzymatic oxidation of retinal to retinoic acid was
not occuring under our culture conditions. Control dishes
containing media and retinal were incubated for 144
hours, with aliquots removed every 24 hours and ana-
lyzed by HPLC. By day 6, less than 1% of the retinal was
oxidized to retinoic acid, suggesting that non-enzymatic
formation or serum-mediated formation of retinoic acid
was not responsible for the observed differentiation in
cells exposed to DEAB or DPAB.
Although DPAB is a more potent inhibitor of human
ALDH1A1 than DEAB, we were concerned that DPAB was
not remaining in solution at 50 µM in the culture media.
However, the observation that the addition of DEAB, a
much more soluble compound, resulted in the same per-
cent inhibition, suggested that solubility was not a factor.
Thus, artifacts due to solubility of inhibitor and extracel-
lular oxidation of retinal do not appear to contribute to
the observed response of DPAB on retinal oxidation.
In addition, the NAD-dependent oxidation of propanal or
retinal was less than 0.05 nmoles NADH formed/min-107
cells in spectrophotometric assays using HL-60 cell ex-
tracts, even in the absence of DEAB or DPAB. The NAD-
dependent oxidation of these aldehydes was not repro-
ducibly detected above background in spectrofluoromet-
ric assays. Therefore, though low levels of ALDH1A1
activity have been reported in HL-60 cells in previous
studies [5,31], it appears that the differentiation observed
in cells exposed to retinal alone or retinal plus DPAB was
not mediated by ALDH1A1 oxidation of retinal to retinoic
acid. One possibility is that a cytochrome P450 (CYP) en-
zyme is catalyzing the oxidation. Raner et al [34] and
Chen et al [35] have described the formation of all-trans
retinoic acid from retinal and retinol by members of the
CYP1 and CYP3A families. In addition, expression of
CYP1A1 and CYP3A4 mRNA has been reported in HL-60
cells [36]. The contribution of ALDH1A2 also can't be
ruled out. However, its activity should be detected by the
spectrophotometric or fluorometric assays.
Although ALDH1A2 appears only to catalyze the oxida-
tion of all-trans retinal to all-trans retinoic acid, both
ALDH1A1 and CYP1 and CYP3A [34] enzymes are capa-
ble of oxidizing 9-cis retinal to 9-cis retinoic acid. The fam-
ily of retinoic acid receptors includes those that bind only
all-trans retinoic acid (RAR α ,β ,γ  and those that bind either
all-trans retinoic acid or 9-cis retinoic acid (RXR α ,β ,γ  Since
the transcriptional regulation of the retinoic acid ligand/
receptor complex appears to involve the binding of recep-
tor heterodimers (RAR/RXR), the specific cellular re-
sponse may depend on the ratio of all-trans to 9-cis
retinoic acid formed, as well as the expression of receptor
subtypes.
Our results suggest an intriguing possibility that regula-
tion of retinoic acid formation in the HL-60 cells, and the
subsequent terminal differentiation to granulocytes,
could be mediated by one enzymatic acitivy, e.g. a CYP-
mediated oxidation of retinal, whereas regulation of retin-
oic acid formation in the hematopoietic stem cells, and
the subsequent maintenance of the self-renewal capacity
of the hematopoietic stem cells, is mediated by ALDH1A1
oxidation of retinal (Figure 3). This hypothesis can be test-
ed by using global or specific CYP inhibitors in the pres-
ence of retinal in HL-60 cells and by using DPAB in the
presence of retinal in an hematopoietic stem cell assay sys-
tem. We are attempting to assess the ability of DPAB to
block retinoic acid formation in cultured, mouse hemat-
opoietic stem cells.
Conclusions
We have shown that DPAB can serve as a potent inhibitor
of purified human and mouse ALDH1A1 and should be a
useful molecule to assess the role of ALDH1A1 in retinal
oxidation in a cell system. In addition, our results indicate
that in HL60 cells, the prototype cell line for studying
retinoic acid induced cell differentiation, ALDH1A1 is not
the operative oxidizing enzyme for retinal.
Table 1: IC50 values for the inhibition by DPAB of the oxidation 
of selected aldehyde substrates by mouse and human ALDH1A1
IC50 of DPAB (µM)
Substrate ALDH1A1
Mouse Human
all-trans Retinal 0.11 ± 0.02 0.13 ± 0.03
Propanal 0.040 ± 0.01 0.14 ± 0.04
Phenylacetaldehyde 0.36 ± 0.04 1.2 ± 0.1
IC50 values are the mean ± average deviation from at least 3 spectro-
photometric assays, each performed in triplicate.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/4
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Materials and methods
Materials
NAD, all-trans retinal, all-trans retinoic acid, dimethylsul-
foxide, mammalian protease inhibitor cocktail, nitroblue
tetrazolium, and pyrazole were obtained from Sigma
Chemical Co., St. Louis, MO. Phenylacetaldehyde, 4-
(N,N-diethylamino) benzaldehyde, and propanal were
purchased from Aldrich Chemical Co., Milwaukee, WI.
Purification of ALDH1A1 from mouse liver and human 
erythrocytes
The purification of ALDH1A1 from mouse liver and hu-
man erythrocytes was performed as in [20].
Substrate and inhibitor preparations
Retinal and retinoic acid were dissolved in either DMSO
or ethanol and stored as 100 mM stock solutions in foil-
wrapped vials at -20°C. For enzyme assays, retinal pre-
pared in DMSO was diluted in a 70% methanol: 30% wa-
ter (v/v) solution and all assays were run under dim light.
DPAB was synthesized as described in [20] and stored as
a yellow oil at 4°C. DPAB was diluted in DMSO to a stock
concentration of 10 mM and then diluted in water prior
to enzyme assays. DMSO concentration did not exceed
0.1% (v/v) in the assay and this concentration had no ef-
fect on enzyme activity.
Figure 2
Differentiation response of HL-60 cells to retinoids and ALDH inhibitors. Retinoid concentrations were 1 µM for all-trans reti-
nal (Ral) and all-trans retinoic acid (RA). Inhibitor concentrations were 50 µM for 4-(N,N-dipropylamino)benzaldehyde (DPAB)
and 4-(N,N-diethylamino)benzaldehyde (DEAB). Control (black squares). Ral (red diamonds). RA (green circles). Ral + DPAB
(dark blue triangles). RA + DPAB (hatched light blue squares). Ral + DEAB (hatched dark red diamonds).BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/4
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Spectrophotometric enzyme assays
ALDH1A1 activity was measured on a Shimadzu UV1201
Spectrophotometer at 36.5° (± 0.5°) at 340 nm. Standard
assay conditions were as follows: 1 mL final reaction vol-
ume; assay buffer (0.1 M sodium pyrophosphate pH 8.4,
1.0 mM EDTA, 5.0 mM dithiothreitol); 1.0 mM NAD; 10
mM pyrazole. The order of addition in the assay was as
follows: buffer; pyrazole; NAD; ALDH (10 mU mouse liv-
er ALDH1A1; 5 mU human erythrocyte ALDH1A1; or HL-
60 cell extract); inhibitor (if any); and lastly, the aldehyde
substrate. One Unit of activity is defined as 1 µmole
NADH formed /minute. Background activity was deter-
mined for 60–90 seconds after the addition of enzyme
and the reaction rate was measured during the 30–60 sec-
onds following addition of retinal substrate Propanal con-
centration was varied from 500 to 10 µM (20–0.4 times
Km), phenylacetaldehyde concentration was varied from
40 to 5 µM (5–0.6 times Km), and retinal concentration
was varied from 1–10 µM, all with constant (1 mM) NAD
concentration. DPAB concentrations were varied from 20
µM to 0.05 µM. All trials were done in triplicate.
HPLC enzyme assays
Since there are three molecules with strong absorbances at
340 nm (retinal, retinoic acid, and NADH), we developed
a high pressure liquid chromatography (HPLC) assay to
assess the ability of DPAB to inhibit retinal oxidation by
class 1 ALDH. Assay conditions were: 0.5 mL final reac-
tion volume; assay buffer (0.1 M sodium pyrophosphate,
pH 8.4, 1.0 mM EDTA, 5.0 mM dithiothreitol or glutath-
ione); 1.0 mM NAD. The reaction rate was measured at
37°C for 1–10 minutes. The reaction was stopped by the
addition of 200 µL butanol. After vortexing for 1 minute,
50 µL of saturated K2HPO4 was added. The sample was
vortexed and centrifuged for 2 minutes at 16,000 g. 50 µL
of the resulting organic layer was injected onto a reverse
phase C18 column (Phenomenex). The mobile phase was
0.5% acetic acid: 20% water: 79.5% acetonitrile (v/v) with
a flow rate of 2.0 mL/min. All-trans retinal and all-trans
retinoic acid were detected at 360 nm with retention times
of 10.0 and 7.7 minutes, respectively.
HPLC assay for detection of retinal purity and stability in 
culture
HPLC was used to analyze the purity of our retinal sam-
ples and the stability of retinal under culture conditions.
The stability of retinal in tissue culture was determined by
incubation of 10 µM retinal in culture media (RPMI 1640
plus 15% fetal bovine serum) for six days at 37°C. At 24
hour intervals, 1 mL of media was removed. 200 mL of
50% butanol:50% acetonitrile (v/v) was added and the
mixture was vortexed for 60 seconds, followed by centrif-
ugation for 2 minutes at 16,000 ×  g. The top organic layer
was removed and diluted 1:5 in acetonitrile before injec-
tion onto the HPLC column.
Cell differentiation assays
HL-60 cells (ATCC, Rockville, MD) were propagated in
RPMI-1640 media supplemented with 15% fetal bovine
serum and 50 U/mL penicillin and 0.5 mg/mL streptomy-
cin. Cells were subcultured and treated at 2 ×  105 cells/
mL. Cells were exposed to combinations of 1 µM retinoic
acid, 1 µM retinal, and various concentrations of DPAB
and DEAB prepared in sterile dimethyl sulfoxide (DMSO)
or ethanol. Final concentrations of DMSO or ethanol in
the culture medium did not exceed 1% v/v. Cells were ex-
posed for up to 144 hours without replacement of media
or washing out of retinoid or inhibitor. Cell differentia-
tion was measured by mixing 100 µL aliquots of cells with
100 µL of a solution containing 1.0% w/v bovine serum
albumin, 0.2% w/v nitroblue tetrazolium and 1.0 µg/mL
of 12-O-tetradecanoylphorbol 13-acetate (TPA). The mix-
ture was incubated for 45 minutes at 37°C in a 24-well
plate. Cells were pipetted onto a Bright Line counting
Figure 3
A schematic depicting the potential roles of different oxida-
tive enzymes in retinoic acid biosynthesis and the differentia-
tion vs. self-renewal response to the retinoic acid ligand at
different stages of hematopoiesis. Hematopoietic stem cell
(HSC). All-trans retinal (Ral). All-trans retinoic acid (RA).
ALDH1A1?BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/4
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chamber and scored as positive for differentiation by the
presence of purple NBT precipitate using bright field mi-
croscopy. Two observers each counted two fields of at
least 200 cells from each well of treated cells. Cell survival
was determined by Trypan blue dye exclusion.
Spectrofluorometric assays for ALDH activity in HL-60 
Cells
Cytosolic extracts of HL-60 cells were analyzed for ALDH
activity using a Perkin Elmer 650 spectrofluorometer with
an excitation wavelength of 350 nM and an emission
wavelength of 460 nM. Assay conditions were as given for
the spectrophotometric enzyme assays above, with pro-
panal or all-trans retinal used as the aldehyde substrate.
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